Faron, etusivu

releases and publications

Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity

Insider Transaction Regulatory

Correction: FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025

Regulatory

FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025

Regulatory

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results

Regulatory

Inside Information: Faron to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA

Regulatory

Faron Pharmaceuticals Ltd: Holding(s) in Company

Shareholder announcement Regulatory

Faron announces extension to its key patent family around bexmarilimab and targeting Clever-1 in cancers with a new US patent granted

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

Regulatory

Inside Information: Faron to present updated BEXMAB data in frontline HR-MDS to FDA; complete remission rate substantially increased to 43%

Regulatory

FARON ANNOUNCES ACCEPTANCE OF BEXMARILIMAB DATA FOR ORAL PRESENTATION AT ESMO 2025

PreviousNext
Back to top